Literature DB >> 21420426

Serological responses following influenza A H1N1 2009 infection in adults.

Sophia Tan1, David L Gordon, Yoshikazu Honda-Okubo, Nikolai Petrovsky, Peter Phillips, Sandra Huddleston, Tania A Sadlon.   

Abstract

OBJECTIVE: The aim of this study was to determine the humoral immune response to influenza A H1N1 2009 and cross reactivity against seasonal H1N1 and H3N2 strains.
METHODS: Baseline and convalescent sera from 88 subjects with confirmed H1N1 2009 were screened for serological responses by HAI assay.
RESULTS: Protective antibody titres to H1N1 2009 were present in 87% post-infection, but varied with age, sex and pregnancy. Some cross reactivity with seasonal influenza strains was observed.
CONCLUSIONS: Females and pregnant subjects had an attenuated immune response to H1N1 2009 in comparison to the rest of the study population. Antibodies from the serum of H1N1 2009 infected subjects cross reacted with seasonal H1N1 and H3N2 influenza viruses.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420426     DOI: 10.1016/j.jinf.2011.03.002

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

1.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Authors:  Yoshikazu Honda-Okubo; Fadi Saade; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

2.  Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Authors:  Nitin Verma; Milena Dimitrova; Donald M Carter; Corey J Crevar; Ted M Ross; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

3.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Authors:  David L Gordon; Dimitar Sajkov; Richard J Woodman; Yoshikazu Honda-Okubo; Manon M J Cox; Susanne Heinzel; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-17       Impact factor: 3.641

4.  High incidence of severe influenza among individuals over 50 years of age.

Authors:  Anna J X Zhang; Kelvin K W To; Herman Tse; Kwok-Hung Chan; Kun-Yuan Guo; Can Li; Ivan F N Hung; Jasper F W Chan; Honglin Chen; Sidney Tam; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

5.  Acceptance and rejection of influenza vaccination by pregnant women in southern Iran: physicians' role and barriers.

Authors:  Behnam Honarvar; Neda Odoomi; Mojtaba Mahmoodi; Golnar Sami Kashkoli; Fatemeh Khavandegaran; Kamran Bagheri Lankarani; Mohsen Moghadami
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

6.  The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity.

Authors:  Ailian Zhang; Danyang Wang; Jinyao Li; Feng Gao; Xucheng Fan
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

7.  Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine.

Authors:  Yoshikazu Honda-Okubo; Harinda Rajapaksha; Dimitar Sajkov; David Gordon; Manon M J Cox; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

8.  Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females.

Authors:  Tanvi Potluri; Ashley L Fink; Kristyn E Sylvia; Santosh Dhakal; Meghan S Vermillion; Landon Vom Steeg; Sharvari Deshpande; Harish Narasimhan; Sabra L Klein
Journal:  NPJ Vaccines       Date:  2019-07-12       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.